Search clinical trials for: GWP42003-P 10 mg/kg/day Dose

Total 646 results

Jazz Pharmaceuticals

Completed

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

Epilepsy | Dravet Syndrome

United States, United Kingdom
Jazz Pharmaceuticals

Completed

Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease

Fatty Liver

United Kingdom
Rockefeller University
Brigham and Women's Hospital; Weill Medical College of Cornell University; University...

Completed

A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

Healthy | HIV

United States, Germany
Jazz Pharmaceuticals

Completed

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE4)

Epilepsy | Lennox-Gastaut Syndrome

United States, Poland, Netherlands
Jazz Pharmaceuticals

Completed

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Epilepsy | Dravet Syndrome

France, United States, United Kingdom, Poland
Rockefeller University
University of Cologne

Completed

A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074

Healthy | HIV

Germany, United States
All India Institute of Medical Sciences, New Delhi

Completed

Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage

Tuberculosis | Drug Induced Hepatotoxicity

India
MacroGenics

Terminated

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) (VOYAGE)

AML

United States, United Kingdom, Germany, Israel, Spain, France, Italy, Netherlands
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
NeuroVive Pharmaceutical AB

Completed

Copenhagen Head Injury Ciclosporin (CHIC) Study (CHIC)

Traumatic Brain Injury

Denmark
ReAlta Life Sciences, Inc.
FGK Clinical Research GmbH

Completed

A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPS

Healthy

Germany
Assiut University

Unknown

Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura

Immune Thrombocytopenia

Egypt
Spanish Society of Critical Care Medicine and Coronary...

Active, not recruiting

Efficacy and Safety of Administration of High Levels of Protein to Critically Ill Patients. (FISIO)

Intensive Care Unit Acquired Weakness

Spain
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Eisai Inc.
Biogen

Completed

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
Second Affiliated Hospital, School of Medicine,...

Recruiting

Prospective Cohort Study of Patients with Early Alzheimer's Disease Treated with Lecanemab

Mild Cognitive Impairment (MCI) | Alzheimer Disease

China
Firas El Chaer, MD

Terminated

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

Hematologic Malignancy | Platelet Refractoriness

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

Major Depressive Disorder

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

Respiratory Syncytial Virus Infections

United States, Australia, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Hungary, Netherlands, New Zealand, Panama, Puerto Rico, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom
The Netherlands Cancer Institute
Roche Pharma AG; Borstkanker Onderzoek Groep

Active, not recruiting

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (TRAIN-2)

Breast Cancer | HER2 Positive

Netherlands
ReAlta Life Sciences, Inc.

Withdrawn

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

COVID-19 | Acute Lung Injury | ALI

United States
Ferring Pharmaceuticals

Terminated

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Sweden, Canada, Hungary, United States, Brazil, South Africa, Czech Republic, Germany, Mexico, Poland, Slovakia, United Kingdom
David Antoniucci
A.R. CARD Onlus Foundation

Terminated

BLeeding Events and Maintenance DoSe of PraSugrel (BLESS)

Acute Coronary Syndrome | Adverse Reaction to Antiplatelet Agent

Italy
Novartis Pharmaceuticals

Completed

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Dry Eye

United States
Rezolute

Recruiting

RZ358 Treatment for Congenital Hyperinsulinism (sunRIZE)

Congenital Hyperinsulinism

United States, France, Georgia, Israel, Spain, Bulgaria, Canada, Denmark, Germany, Greece, Oman, Qatar, Saudi Arabia, United Arab Emirates, United Kingdom, Vietnam, Turkey
QED Therapeutics, Inc.

Enrolling by invitation

An Interventional Study of Infigratinib in Children With Hypochondroplasia (HCH)

Hypochondroplasia

United States, Singapore, Norway, Australia, France, Canada, Portugal, United Kingdom, Spain, Sweden
Nuritas Ltd

Completed

A Study to Determine the Safety and Tolerability of a Range of Doses of PeptiControl in Pre-diabetic Individuals

Overweight | Pre Diabetes

India
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Ozlem Goker-Alpan
Team Sanfilippo

Not yet recruiting

An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III

Sanfilippo Syndrome | MPS3

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumor

China
University of California, San Francisco

Completed

Increasing Fluids in Older Adults to Prevent & Treat Pressure Ulcers

Pressure Ulcers
Cardiox Corporation

Withdrawn

Cardiox Liver Function Test Pivotal Trial (LFT-0002)

Liver Failure | Hepatic Failure

United States
University of South Florida
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Iron Supplementation and Intestinal Health

Very Low Birth Weight Infant | Anemia of Prematurity

United States
Novartis Pharmaceuticals

Completed

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, United Kingdom
Ludwig Institute for Cancer Research
Daiichi Sankyo Co., Ltd.; Austin Health

Completed

Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers (LUD2014-002)

Malignant Solid Tumor | Metastatic EphA2 Positive Cancer

Australia
Eisai Inc.

Completed

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Idiopathic Thrombocytopenic Purpura

United Kingdom
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Warner Chilcott

Completed

Treatment of Moderate to Severe Facial Acne Vulgaris

Acne Vulgaris

United States
Viridian Therapeutics, Inc.

Active, not recruiting

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants with Thyroid Eye Disease (TED) (STRIVE)

Thyroid Eye Disease

Spain, United States, France, Germany, Poland, United Kingdom, Australia
The First Hospital of Jilin University

Not yet recruiting

Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

HER2 Positive Breast Cancer
BioMarin Pharmaceutical

Terminated

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, Netherlands, France, United Kingdom, Italy
Lpath, Inc.

Completed

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

Healthy Subjects

United States
Centre for Addiction and Mental Health

Completed

Cannabis Edibles and Simulated Driving

Cannabis | Driving Under the Influence

Canada
Pfizer

Completed

A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Sweden
Bill & Melinda Gates Medical Research Institute

Completed

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Malaria

United States
Alexion Pharmaceuticals

Terminated

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease (GIGVHD)

Acute Graft-Versus-Host Disease | GIGVHD

United States, France

Search clinical trials for: GWP42003-P 10 mg/kg/day Dose

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations